SCHEMBL30694129

SCHEMBL30694129

COC(=O)c1ccc2c(n1)C(=O)CCC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A15 Q9H2J7 1/20 0.40
MAPK1 P28482 1/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 3/20 0.38
GAA P10253 2/20 0.38
HSD17B10 Q99714 2/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
PARP1 P09874 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.35
BAZ2B Q9UIF8 1/20 0.35
TSHR P16473 1/20 0.35
MAPT P10636 2/20 0.35
POLB P06746 2/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
CYP1A2 P05177 2/20 0.35
RECQL P46063 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28956536 0.83 BAZ2B (0.38) KDM4EALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL6766148 0.81 ALDH1A1 (0.41) KDM4EALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL13977966 0.80 KDM4E (0.43) MAPK1KDM4EALDH1A1HPGDGAA
SCHEMBL29550177 0.77 SLC6A15 (0.39) SLC6A15MAPK1PARP1
SCHEMBL10209783 0.77 SLC6A15 (0.39) SLC6A15MAPK1PARP1
SCHEMBL5053548 0.76 KDM4E (0.46) MAPK1KDM4EALDH1A1HPGDGAA
SCHEMBL30640279 0.76 GRM5 (0.43) MAPK1KDM4EALDH1A1HPGDGAA
SCHEMBL10017919 0.76 GRM5 (0.43) MAPK1KDM4EALDH1A1HPGDGAA
SCHEMBL28968802 0.75 CNR2 (0.46) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL874647 0.74 ALDH1A1 (0.37) KDM4EALDH1A1HPGDHSD17B10L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195513-A1 DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEIGENE, LTD. (KY) 2025-06-19 US disclosed
EP-4536664-A1 DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BeiGene, Ltd. (KY) 2025-04-16 EP disclosed
CN-119403805-A Degradation of IRAK4 by conjugation of IRAK4 inhibitors to E3 ligase ligands and methods of use 百济神州有限公司 2025-02-07 CN disclosed
WO-2023237049-A1 DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEIGENE, LTD. (KY) 2023-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195513-A1 DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE IRAK4, IRAK2, IRAK3 SLC6A15 4476/4885MAPK1 1825/4885KDM4E 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.